This study looks into the effects of a drug called efimosfermin on people with a liver condition called MASH, which stands for metabolic dysfunction associated steatohepatitis. MASH can lead to liver scarring, known as cirrhosis. Cirrhosis is when the liver gets damaged and scarred, making it hard for the liver to work properly. The study focuses on people with compensated cirrhosis, meaning their liver is damaged but still manages to function.

Participants need to be between 18 and 75 years old and have at least two signs of metabolic syndrome, which includes conditions like high blood pressure, high blood sugar, extra body fat, and abnormal cholesterol levels. A liver biopsy, which is a tiny piece of the liver taken for testing, must confirm MASH with stage F4 fibrosis, a type of severe scarring.

• Study length: Specific duration not mentioned, but participation involves multiple visits.
• Compensation: Not specified, but often studies offer some form of compensation.
• Risks: Must not have other liver diseases or type 1 diabetes.